
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

